At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLXN Silexion Therapeutics Corp
Not Yet Opened 06-02 16:00:00 EDT
4.99
+0.01
+0.20%
盘后4.98
-0.01-0.20%
19:50 EDT
High5.10Low4.34Vol93.99K
Open4.80D1 Closing4.98Amplitude15.35%
Mkt Cap2.09MTradable Cap2.02MTotal Shares419.00K
T/O442.34KT/O Rate23.26%Tradable Shares404.00K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Silexion Therapeutics executes 1-for-10 reverse share split
Reuters  ·  05-29
Silexion Therapeutics executes 1-for-10 reverse share split
Silexion Therapeutics Corp trading halted, news pending
TIPRANKS  ·  05-29
Silexion Therapeutics Corp trading halted, news pending
Silexion Therapeutics announces 1-for-10 reverse share split
Reuters  ·  05-26
Silexion Therapeutics announces 1-for-10 reverse share split
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
THOMSON REUTERS  ·  05-26
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Top Premarket Gainers
MT Newswires Live  ·  05-20
Top Premarket Gainers
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
THOMSON REUTERS  ·  05-18
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Silexion net loss widens 58.8% to USD 2.73 million in Q1 2026
Reuters  ·  05-16
Silexion net loss widens 58.8% to USD 2.73 million in Q1 2026
Silexion Therapeutics sells unregistered warrants for 3990184 shares at $0.5 each
Reuters  ·  05-16
Silexion Therapeutics sells unregistered warrants for 3990184 shares at $0.5 each
Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds
Reuters  ·  05-15
Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
GlobeNewswire  ·  05-15
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for Sil204 in Kras-Driven Pancreatic Cancer
THOMSON REUTERS  ·  05-14
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for Sil204 in Kras-Driven Pancreatic Cancer
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
GlobeNewswire  ·  05-14
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204
TIPRANKS  ·  05-14
Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204
Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer
Reuters  ·  05-13
Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer
Silexion Therapeutics Announces Initiation of Gmp Clinical Supply Manufacturing of Sil204 With Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
THOMSON REUTERS  ·  05-13
Silexion Therapeutics Announces Initiation of Gmp Clinical Supply Manufacturing of Sil204 With Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)
TIPRANKS  ·  04-29
Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)
Silexion Therapeutics submits SIL204 clinical trial application to Germany
TIPRANKS  ·  04-28
Silexion Therapeutics submits SIL204 clinical trial application to Germany
Silexion submits Germany trial application for SIL204 pancreatic cancer study
Reuters  ·  04-28
Silexion submits Germany trial application for SIL204 pancreatic cancer study
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s Bfarm for Sil204 in Kras-Driven Locally Advanced Pancreatic Cancer
THOMSON REUTERS  ·  04-28
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s Bfarm for Sil204 in Kras-Driven Locally Advanced Pancreatic Cancer
Silexion Therapeutics removes Ilan Levin from board; change effective immediately
Reuters  ·  03-26
Silexion Therapeutics removes Ilan Levin from board; change effective immediately

Introduction

Company Name.
Silexion Therapeutics Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.
Issue price:
--